Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Exploiting Leading Edge 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients. The investigators hypothesize that Filgotinib's mechanism of analgesic action is determined by at least two factors. The first is related to those CNS sensitization pathways seen in fibromyalgia, specifically DMN-insula brain functional connectivity and insular glutamate. The second is related to peripheral inflammation, specifically joint synovitis, blood cytokines/chemokines and DAN-LIPL functional brain connectivity. The CNS sensitization pain pathways related to fibromyalgia are more quickly modified compared to those related to peripheral inflammation and help explain Filgotinib's rapid onset of effect.

Who May Be Eligible (Plain English)

Who May Qualify: Patients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are: - Adults ≥18 years \< 75 years. - Right-handed (to reduce neuroimaging heterogeneity). Who Should NOT Join This Trial: - Inability to provide written willing to sign a consent form. - Severe physical impairment (e.g. blindness, deafness, paraplegia). - Pregnant or breast feeding. - Severe claustrophobia precluding MRI. - Contraindications to MRI. - Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury. - Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: Patients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are: * Adults ≥18 years \< 75 years. * Right-handed (to reduce neuroimaging heterogeneity). Exclusion Criteria: * Inability to provide written informed consent. * Severe physical impairment (e.g. blindness, deafness, paraplegia). * Pregnant or breast feeding. * Severe claustrophobia precluding MRI. * Contraindications to MRI. * Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury. * Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA.

Locations (1)

Neil Basu
Glasgow, United Kingdom